
Join to View Full Profile
410 W 10th Ave E419Columbus, OH 43210
Phone+1 614-293-5905
Fax+1 614-293-4715
Are you Dr. Tozbikian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Gary Tozbikian, MD is a board certified pathologist in Columbus, Ohio. He is currently licensed to practice medicine in Ohio, Pennsylvania, and Pennsylvania. He is an Assistant Professor at Ohio State University College of Medicine.
Education & Training
- University of Pennsylvania Health System GI/Hepatic PathologyFellowship, Selective Pathology, 2011 - 2012
- University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 2007 - 2011
- Ohio State University College of MedicineClass of 2007
Certifications & Licensure
- OH State Medical License 2013 - 2025
- PA State Medical License 2007 - 2012
- PA State Medical License 2007 - 2012
- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
Publications & Presentations
PubMed
- Clinicopathologic Characteristics and Follow-Up Outcomes of Invasive Breast Carcinoma With Different Positive HER2 Fluorescence In Situ Hybridization Patterns: Experie...Zaibo Li, Yan Hu, Dan Jones, Weiqiang Zhao, Gary Tozbikian
Modern Pathology. 2025-01-01 - Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?Paulina J Haight, Sydney Lammers, Quinn Kistenfeger, Chelsea Leipold, Adrian A Suarez
Gynecologic Oncology. 2024-12-01 - 1 citationsBest practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists.Gary Tozbikian, Marilyn M Bui, David G Hicks, Shabnam Jaffer, Thaer Khoury
Histopathology. 2024-09-01
Press Mentions
- PD-L1 Testing in Triple-Negative Breast Cancer: Post Hoc IMpassion130 Substudy Evaluates PD-L1 IHC Assay PerformanceApril 1st, 2020